Bcl-2 antibody (AA 41-54)

Catalog No. ABIN3026595

Product Details anti-Bcl-2 Antibody

Target: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Binding Specificity: AA 41-54

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Bcl-2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

No Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Characteristics: This antibody recognizes a protein of 25-26 kDa, identified as the Bcl-2 alpha oncoprotein. It shows no cross-reaction with Bcl-x or Bax protein. Expression of Bcl-2 alpha oncoprotein inhibits the programmed cell death (apoptosis). In most follicular lymphomas, neoplastic germinal centers express high levels of Bcl-2 alpha protein, whereas the normal or hyperplastic germinal centers are negative. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. It may also be used in distinguishing between those follicular lymphomas that express Bcl-2 protein and the small number in which the neoplastic cells are Bcl-2 negative.

Purification: Protein G affinity chromatography

Immunogen: A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human Bcl-2 protein was used as the immunogen for this antibody.

Clone: 124

Isotype: IgG1 kappa

Application Details

Application Notes: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 1  mM EDTA Buffer,  pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. ELISA: order BSA-free format for coating,FACS: 0.5-1 μg/million cells,IF: 0.5-1 μg/mL,WB: 0.5-1 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1)

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the Bcl-2 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for Bcl-2

Target: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Alternative Name: Bcl-2 (BCL2 Products)

Synonyms: Bcl-2 antibody, PPP1R50 antibody, bcl-2 antibody, AW986256 antibody, C430015F12Rik antibody, D630044D05Rik antibody, D830018M01Rik antibody, BCL-2 antibody, Bcl2 antibody, BCL2, apoptosis regulator antibody, B cell leukemia/lymphoma 2 antibody, B-cell CLL/lymphoma 2a antibody, B-cell CLL/lymphoma 2 protein antibody, BCL2 antibody, Bcl2 antibody, bcl2a antibody, BCL-2 antibody

Background: This antibody recognizes a protein of 25-26  kDa, identified as the Bcl-2 alpha oncoprotein. It shows no cross-reaction with Bcl-x or Bax protein. Expression of Bcl-2 alpha oncoprotein inhibits the programmed cell death (apoptosis). In most follicular lymphomas, neoplastic germinal centers express high levels of Bcl-2 alpha protein, whereas the normal or hyperplastic germinal centers are negative. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. It may also be used in distinguishing between those follicular lymphomas that express Bcl-2 protein and the small number in which the neoplastic cells are Bcl-2 negative.

Gene ID: 596

Pathways: MAPK Signaling, PI3K-Akt Signaling, Apoptosis, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling